COMMUNIQUÉ DE PRESSE publié le 29/02/2024 à 22:05, il y a 6 mois 18 jours Sonnet BioTherapeutics Announces a Publication Demonstrating Safety and Tolerability of SON-1010 in Healthy Volunteers Sonnet BioTherapeutics Holdings, Inc. announced the publication of clinical data on SON-1010, a tumor-targeted immunotherapeutic drug combining FHAB construct with IL-12 in Frontiers in Immunology, showing favorable safety and tolerability Clinical Data Sonnet BioTherapeutics SON-1010 Immunotherapeutic Drug FHAB Technology
COMMUNIQUÉ DE PRESSE publié le 14/02/2024 à 13:30, il y a 7 mois 4 jours Sonnet BioTherapeutics Provides Fiscal Year 2024 First Quarter Business and Earnings Update Sonnet BioTherapeutics Holdings, Inc. successfully raised $4.55 million, published preclinical data on SON-1210, executed NJ NOLs agreement, Phase 1b SON-080 trial enrollment completed, financial results announced for quarter ended Dec 31, 2023 Financial Results Preclinical Data Public Offering Sonnet BioTherapeutics Holdings NJ NOLs
COMMUNIQUÉ DE PRESSE publié le 21/12/2023 à 14:00, il y a 8 mois 28 jours Sonnet BioTherapeutics Announces Publication Demonstrating Suitability of SON-1210, the First Albumin-binding Bifunctional IL-12/IL-15 Fusion Protein, for Solid Tumor Immunotherapy
COMMUNIQUÉ DE PRESSE publié le 14/12/2023 à 22:15, il y a 9 mois 4 jours Sonnet BioTherapeutics Provides Fiscal Year 2023 Business and Financial Update
COMMUNIQUÉ DE PRESSE publié le 31/10/2023 à 12:30, il y a 10 mois 18 jours Sonnet BioTherapeutics Provides Fiscal Year 2023 Business Overview
COMMUNIQUÉ DE PRESSE publié le 25/10/2023 à 13:30, il y a 10 mois 24 jours Sonnet BioTherapeutics Announces Pricing of $4.55 Million Underwritten Public Offering
COMMUNIQUÉ DE PRESSE publié le 17/10/2023 à 14:00, il y a 11 mois 1 jour Sonnet BioTherapeutics Announces Abstract Accepted for Presentation by a Key Opinion Leader at the 2023 Connective Tissue Oncology Society (CTOS) Annual Meeting
COMMUNIQUÉ DE PRESSE publié le 20/09/2023 à 13:30, il y a 11 mois 28 jours Sonnet BioTherapeutics Announces Results of Biodistribution Studies Demonstrating Solid Tumor Targeting Using the FHAB Technology
Publié le 18/09/2024 à 18:45, il y a 8 heures 52 minutes Augmentation de capital consécutive à l'attribution gratuite d'actions aux salariés du groupe EuropaCorp
Publié le 18/09/2024 à 18:45, il y a 8 heures 52 minutes Capital increase following the allocation of free shares to EuropaCorp employees
Publié le 18/09/2024 à 17:40, il y a 9 heures 57 minutes Groupe CRIT : Modalités de mise à disposition du Rapport Financier semestriel 2024.
Publié le 19/09/2024 à 03:20, il y a 17 minutes How to Sell a Business Online Guide for Small Business Owners Released by the Business Brokers Directory
Publié le 18/09/2024 à 23:10, il y a 4 heures 27 minutes Ur-Energy Provides Operations, Construction and 2024 Guidance Updates
Publié le 18/09/2024 à 23:00, il y a 4 heures 37 minutes Garden State Gold & Coin Applauds Passage of Historic NJ Sales Tax Bill on Precious Metals
Publié le 18/09/2024 à 21:15, il y a 6 heures 22 minutes New to the Street Launches 24-Part Series with ARAX Holdings, Spotlighting Core Blockchain, CorePass, Lunaº Mesh, and Revolutionary Tech Solutions
Publié le 18/09/2024 à 21:00, il y a 6 heures 37 minutes Falcon Commences Drilling At Its Great Burnt Copper Project, NL
Publié le 18/09/2024 à 19:11, il y a 8 heures 26 minutes EQS-Adhoc: alstria office REIT-AG: squeeze-out demand regarding the shares of minority shareholders, amendment to investment agreement, loss of REIT-status at year-end 2024
Publié le 18/09/2024 à 18:45, il y a 8 heures 52 minutes Fuller, Smith & Turner PLC: Transaction in own shares
Publié le 18/09/2024 à 18:31, il y a 9 heures 6 minutes EQS-Adhoc: Vonovia SE: Initiation of the process to conclude a domination and profit and loss transfer agreement between Vonovia SE and Deutsche Wohnen SE
Publié le 18/09/2024 à 18:13, il y a 9 heures 24 minutes BILENDI: Creating discussion guides for market research is now possible with AI, thanks to BARI and Bilendi Discuss
Publié le 18/09/2024 à 17:21, il y a 10 heures 16 minutes EQS-Adhoc: Marinomed Biotech AG resolves capital increase excluding statutory subscription rights by issuing 154,053 no-par value bearer shares at an issue price of EUR 5 per share